$65m takes liver disease treatments to new dimension

US-based life sciences firm Dimension Therapeutics has raised $65m in its series B to advance development of its gene therapy treatments for rare diseases with a focus on the liver.

New Leaf Venture Partners led the round, and was joined by fellow new investors Jennison Associates, Partner Fund Management, RA Capital Management, Rock Springs Capital, and Tourbillon Global Ventures, as well as existing investors Fidelity Biosciences and OrbiMed.

Dimension has now raised $124.5m through its series B, a $24.5m private equity round, $30m in series A, and a $5m venture round in 2013.

Dimension, established in 2013, has partnered with Pennsylvania University and pharma Regenxbio on its development, and also has a collaboration deal with Bayer.

Annalisa Jenkins, CEO at Dimension, said: “Over the past year, Dimension has raised more than $100 million, including our Series A round, as well as a $20 million upfront payment we received from partner Bayer HealthCare last June. We are well-capitalised for the next stage of our development as we advance our lead programs into the clinic and continue to expand our R&D pipeline focused on rare diseases associated with the liver.”